Medicalgorithmics SA stock news
Medicalgorithmics SA has released its estimated financial results for the second quarter of 2026, reporting a 55% year--over--year increase in consolidated sales revenue to PLN 10.8 million. The company achieved a positive EBITDA of PLN 1.2 million, marking a significant improvement from the PLN 0.95 million loss recorded in the same period of 2025. Growth was largely driven by the U.S. market, where revenue more than doubled to PLN 4.7 million, alongside a total of 118,174 ECG analysis sessions performed. Following these results, the management board announced a new policy to regularly publish preliminary quarterly financial data to enhance transparency for investors.